Core Insights - The report continues to recommend innovative drugs and the related industry chain, highlighting the strong growth potential in the pharmaceutical sector through 2026 [1][4]. Investment Strategy - The investment strategy emphasizes the focus on the CXO sector, particularly in chemical CDMO, where Chinese companies hold significant advantages in talent, chemical capabilities, compliance production, and intellectual property protection [4]. - The report suggests that the upcoming JPM conference will provide updates on the operational progress of Chinese innovative drug companies, which have shown a long-term positive development trend [4]. - The recommended investment portfolio includes A-shares such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, as well as H-shares like Kangfang Biologics and WuXi Biologics [4][5]. Industry Performance - The pharmaceutical industry experienced a decline of 4.10% in December, underperforming the CSI 300 index by 6.38% [8]. - The report notes that the chemical pharmaceutical sector saw the largest declines among sub-sectors, with a drop of 5.80% [12]. Market Data - For the period from January to November 2025, the pharmaceutical manufacturing industry's total revenue was 220.65 billion yuan, reflecting a year-on-year decrease of 2.0% [7]. - The total retail sales of consumer goods reached 45.61 trillion yuan, with retail sales of Western and Chinese medicines amounting to 660.4 billion yuan, a year-on-year increase of 1.8% [7]. Regulatory Environment - The report discusses the impact of the U.S. "Biological Safety Act," which is expected to have a limited short-term effect on Chinese CXO companies, while emphasizing the need to monitor the long-term implications of international competition and regulatory changes [22]. Recent Drug Approvals - In December 2025, a total of 16 innovative drugs or biosimilars were approved for market entry, including six domestic and ten imported products [24][25].

Group 1 - The current market rally, referred to as "开门红," is supported by improving macroeconomic data and ample liquidity, which enhances market risk appetite and attracts new capital inflows [1][9][40] - Various types of trading funds have shown accelerated entry into the market, including a net inflow of 78.9 billion yuan in margin financing since the beginning of the year and an average daily net inflow of retail funds returning to around 30 billion yuan [1][9][40] - The structural consensus among different types of funds is strong, focusing on sectors such as TMT (storage, AI applications), military (commercial aerospace), non-ferrous metals, new energy (controlled nuclear fusion), machinery (robots), and pharmaceuticals (innovative drugs, brain-machine interfaces) [2][35][38] Group 2 - The global stock market is experiencing a strong start in 2026, driven by expectations of loose liquidity, geopolitical changes, and emerging industrial trends, with A-shares reflecting this global narrative [5][38] - Key events such as the International Consumer Electronics Show (CES) and geopolitical developments are catalyzing themes in the market, enhancing the strategic value of resource products and driving structural similarities across global markets [5][38] - The market is currently in a favorable position with limited downside risk and significant potential for upward movement, supported by improved PMI and price data, as well as a high percentage of stocks still below their previous highs [11][44] Group 3 - The recent surge in the commercial aerospace sector has raised concerns about its current crowding and sustainability, with trading volume indicating a potential for further upward movement [16][51] - As the earnings forecast disclosure period approaches, the correlation between stock prices and earnings will increase, necessitating a focus on structural adjustments based on performance [21][57] - Industries with significant upward revisions in profit forecasts since November include technology (consumer electronics, computing), advanced manufacturing (new energy, military), and cyclical sectors (building materials, non-ferrous metals) [26][58]

Group 1 - The China Eye Health Industry Park Alliance was established during the conference, aiming to create a collaborative mechanism among leading eye health industry parks in China [1][3] - The conference emphasized the theme of "Ecological Co-construction and Win-win Cooperation," focusing on collaboration in areas such as industrial park synergy, open sharing of innovative resources, and efficient transformation of technological achievements [1][2] - The Changping District has developed a comprehensive industrial chain in the medical and health sector, with nearly 3,000 health enterprises and an industry revenue exceeding 100 billion yuan [1][2] Group 2 - The International Smart Medical Engineering Innovation Center was established to integrate clinical needs, research innovation, and industrial transformation, gathering key companies in the eye health sector [2][3] - The center aims to enhance the development of high-end ophthalmic instruments and medications, promoting the establishment of a leading eye health industry cluster in China [2][3] - The center is supported by various organizations, including Tsinghua University and the China Medical Equipment Association, and is located in the International Medical Device City in Changping District [3] Group 3 - Tupu Medical, founded in 2017, is one of the largest ophthalmic medical device companies in China, with a comprehensive product line that competes with global leaders [4] - The company has established a strong presence in multiple cities and focuses on high-end ophthalmic equipment, including OCT and surgical microscopes [4] - Tupu Medical is recognized for its ability to compete with Zeiss across its entire product line, positioning itself as a full-platform supplier of high-end ophthalmic instruments [4]

进一步统计，近3个月内该股累计发生7笔大宗交易，合计成交金额为7084.28万元。该股近5个交易日累 计上涨4.01%，主力资金合计净流入6746.8万元。 责任编辑：小浪快报 1月9日，爱尔眼科收涨0.97%，收盘价为11.42元，发生1笔大宗交易，合计成交量22.1万股，成交金额 249.95万元。 第1笔成交价格为11.31元，成交22.10万股，成交金额249.95万元，溢价率为-0.96%，买方营业部为华泰 证券股份有限公司成都锦晖西二街证券营业部，卖方营业部为华泰证券股份有限公司成都锦晖西二街证 券营业部。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ ...

爱尔眼科1月9日大宗交易平台出现一笔成交，成交量22.10万股，成交金额249.95万元，大宗交易成交价 为11.31元，相对今日收盘价折价0.96%。该笔交易的买方营业部为华泰证券股份有限公司成都锦晖西二 街证券营业部，卖方营业部为华泰证券股份有限公司成都锦晖西二街证券营业部。 进一步统计，近3个月内该股累计发生7笔大宗交易，合计成交金额为7084.28万元。 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 22.10 | 249.95 | 11.31 | -0.96 | 华泰证券股份有限公司成 | 华泰证券股份有限公司成 | | | | | | 都锦晖西二街证券营业部 | 都锦晖西二街证券营业部 | （文章来源：证券时报网） 证券时报·数据宝统计显示，爱尔眼科今日收盘价为11.42元，上涨0.97%，日换手率为0.78%，成交额为 7.11亿元，全天主力资金净流入792.30万元， ...

Investment Rating - The report gives a "Market Perform" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [26][32]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 3.61% from December 26, 2025, to January 8, 2026, exceeding the CSI 300 index by approximately 1.56 percentage points [12]. - Most sub-sectors within the industry recorded positive returns during the same period, with the hospital and medical R&D outsourcing sectors leading with increases of 10.62% and 7.39%, respectively [13]. - Approximately 82% of stocks in the industry achieved positive returns, with notable performers including Xiangyu Medical, which saw a weekly increase of 57.50% [14][17]. - The overall industry valuation has risen, with the SW pharmaceutical and biotechnology index's PE (TTM) at approximately 52.75 times, which is 3.78 times higher than the CSI 300 index [18][26]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 3.61% from December 26, 2025, to January 8, 2026 [12]. - Most sub-sectors recorded positive returns, particularly hospitals and medical R&D outsourcing, which increased by 10.62% and 7.39%, respectively [13]. - About 82% of stocks in the industry had positive returns, with significant gains from several companies [14]. 2. Industry News - The report highlights the acceleration of volume-based procurement in 2026, with various local and national initiatives underway to streamline drug procurement processes [24]. - A new batch of encouraged generic drugs has been announced, focusing on optimizing the drug supply system and enhancing the availability of essential medications [23]. 3. Company Announcements - Jiangsu Yahui Pharmaceutical announced the completion of the first patient enrollment in a Phase I clinical trial for its drug APL-2401, targeting advanced solid tumors [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, particularly following announcements from Neuralink regarding large-scale production plans [26]. - Recommended stocks for attention include leading companies in medical devices, pharmaceutical retail, aesthetic medicine, and innovative drugs, among others [28][29].

Core Viewpoint - The successful implementation of the EVO+ICL(V5) surgery at Shanghai Aier Eye Hospital marks a significant advancement in vision correction technology, particularly for individuals with high demands for night vision quality, offering a revolutionary "day and night high-definition" experience [1][8]. Group 1: Technology and Innovation - The EVO+ICL(V5) technology features an expanded optical zone design that effectively reduces night glare and halos, making it particularly suitable for individuals with high night vision requirements [2][4]. - The new ICL technology can correct a wide range of vision issues, accommodating myopia from 50 to 1400 degrees and astigmatism up to 600 degrees, while being reversible and not requiring corneal cutting [2][4]. - The EVO+ICL(V5) lens has an optical zone that expands to 7.6mm, significantly improving night vision by better covering the dark pupil [4]. Group 2: Material and Manufacturing - The lens is made from a unique Collamer material, which offers high biocompatibility, flexibility, effective UV blockage, and excellent long-term safety, ensuring a stable and lasting high-definition visual experience [5]. - The manufacturing process utilizes Swiss precision engineering, focusing on meticulous detail and continuous innovation to provide cutting-edge visual quality [6]. Group 3: Clinical Validation and Experience - The ICL technology has been validated through over 30 years of clinical practice, with more than 3 million lenses implanted globally across 75 countries, highlighting its reliability and acceptance among both doctors and patients [7]. - The successful surgery at Shanghai Aier Eye Hospital reflects the institution's strong technical capabilities, supported by a history of completing 550,000 ICL surgeries by 2025 and extensive experience in correcting high myopia and complex refractive errors [8][9]. Group 4: Future Directions - The hospital aims to continue introducing and applying globally leading technologies to meet the diverse and refined visual needs of urban residents, emphasizing a patient-centered approach in providing safe, precise, and clear vision correction solutions [9].

Group 1 - The company, Aier Eye Hospital Group, focuses on ophthalmology and is committed to keeping up with advancements in interdisciplinary fields [1]

Group 1 - The core viewpoint of the article is that Aier Eye Hospital (300015) is collaborating with iFlytek (002230) to enhance service quality through innovative applications and complementary strengths [1] Group 2 - The partnership aims to explore various application scenarios to benefit a wide range of patients [1]

Group 1 - The core viewpoint of the article is that Aier Eye Hospital (300015) has successfully achieved mass production of its "Little Green Sprout" series products, which are reported to have effective myopia prevention capabilities [1] Group 2 - The "Little Green Sprout" series products are designed to address myopia, indicating a focus on eye health and preventive care in the ophthalmology sector [1] - The announcement was made in response to investor inquiries on the company's interactive platform, highlighting the company's engagement with its investors [1]